INTERNEURON DEXFENFLURAMINE COGNITIVE STUDY FINDS NO EVIDENCE OF NEUROTOXICITY; ADVISORY COMMITTEE RECOMMENDS OBESITY THERAPY BY SLIM MARGIN

A 72-patient study of Interneuron's Redux (dexfenfluramine) assessing cognitive function provides a "reassuring lack of evidence of neurotoxicity," FDA Medical Officer Leo Lutwak, MD/PhD, told the Endocrinologic & Metabolic Drugs Advisory Committee Nov. 16.